China Grants Patent to COVID-19 Vaccine

The first invention patent to a COVID-19 vaccine has been granted by China. The vaccine is a recombinant adenovirus vaccine named Ad5-nCoV co-developed by CanSino.

The first invention patent to a COVID-19 vaccine has been granted by China. The COVID-19 vaccine was co-developed by biopharmaceutical firm CanSino Biologics Inc in the country, which experts said demonstrates the vaccine's originality and creativity.

According to a Global Times report, the vaccine is a recombinant adenovirus vaccine named Ad5-nCoV co-developed by CanSino with a team led by Chinese military infectious disease expert Chen Wei.

Mass Production of COVID-19 Vaccine Begins In Russia
Russia has begun production of the first batch of vaccines against COVID-19, its health ministry said in a statement released on Saturday.

‘China has granted the first patent to indigenously developed COVID vaccine.’

"The grant of the patent further confirmed the vaccine's efficacy and safety, and convincingly demonstrated the ownership of its intellectual property rights (IPR)," CanSino said in a statement on Sunday.

An officially granted patent would enhance the market's confidence in Chinese-developed Covid-19 vaccines, "especially that of the international market".

"The US has been making accusations since May that Chinese hackers were attempting to steal novel coronavirus data on treatments and vaccines without providing substantial evidence," said the report.

COVID-19 Vaccine Helps Prevent Pneumonia
In mice infected with the COVID-19 virus, an experimental vaccine was found to help prevent pneumonia, stated new study.

According to CanSino, they applied for a patent with the National Intellectual Property Administration on March 18, three days after they launched phase one clinical trials on the candidate and received approval on August 11.

The phase III trial on the vaccine "which will be conducted overseas is progressing smoothly," the company said in the statement.

New Protein Aids COVID-19 Vaccine Development
The experimental vaccine against SARS-CoV-2 has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.

CanSino has signed deals with Mexico to conduct late-stage clinical trials for Covid-19 vaccines.

Saudi Arabian health officials also announced on August 9 to cooperate with phase III clinical trials on the vaccine, recruiting around 5,000 participants.

Russia Bats for Safety of Its COVID-19 Vaccine
COVID-19 vaccine developed by Russia in partnership with the Gamaleya Scientific Research Institute of Epidemiology and Microbiology appears to be safe.

CanSino has also reportedly been in talks with Russia, Brazil and Chile to launch a Phase III trial on Ad5-nCOV.

Meanwhile, Russia has begun production of the first batch of vaccines against Covid-19, its health ministry said in a statement over the weekend.

The world's first registered vaccine against the novel coronavirus was announced by President Vladimir Putin last week, during an online meeting with government officials.

The third stage of the research on the world's first registered vaccine against the novel coronavirus, called Sputnik V, may begin in 7-10 days.

According to the Tass news agency, several tens of thousands of people are expected to take part in this research of the vaccine created by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Russian Health Ministry.

The vaccine Sputnik V, which is named after the space satellite launched by Moscow in 1957, was created by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, alongside the Russian Direct Investment Fund.

Source-IANS